Turnover: 1.34 billion EUR (2021)
Country: Germany
Founded in 1908 in Frankfurt, Merz is a pharmaceutical company and a family business that is now present in 28 countries around the world and whose products are also distributed in 90 other countries. The group's businesses are divided into four areas: beauty and aesthetics, dermatology, neurology, and self-medication and wellness.
The latter business is developed by the Merz Aesthetics division (https://www.merzaesthetics.com), which offers drugs for plastic surgery professionals, medical devices and equipment, and hyaluronic acid-based fillers. The group's aesthetics division accounted for about 50 percent of Merz Pharmaceuticals' 2017 sales. The company has recently expanded its business into noninvasive aesthetic medicine, and is now one of the leading suppliers of botulinum toxin in the world. In 2010, the German group launched a €191 million takeover bid for rival BioForm Medical, acquiring a number of filler products. The three main aesthetic medicine brands in Merz's portfolio are Belotero, Radiesse and BoCouture Xeomin.
Financial Data
DUNS: 492060215
Legal Name: MERZ PHARMA FRANCE
Address: 2 AVENUE GAMBETTA TOUR EQHO, 92400 COURBEVOIE
Number of employees: Entre 20 et 49 salariés (2021)
Capital: 862 485 EUR
Financial Data:
| Year | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Turnover | 30 605 736 | 26 570 108 | 22 978 638 | 19 854 860 | 21 193 845 | 19 894 748 | 18 955 831 | 15 477 312 | 13 265 766 |
| Gross margin (€) | 17 954 106 | 16 579 176 | 12 559 796 | 12 150 603 | 12 129 700 | 13 340 272 | 12 163 146 | 10 255 640 | 9 509 737 |
| EBITDA (€) | 315 992 | 1 306 868 | 2 111 858 | 1 043 382 | 345 808 | 569 749 | 2 390 304 | 498 742 | -161 119 |
| Operating profit (€) | 753 897 | 1 785 254 | 991 764 | 747 347 | 251 945 | 692 652 | 1 583 819 | 645 971 | -52 149 |
| Net profit (€) | 559 776 | 1 424 537 | 353 046 | 440 720 | -201 581 | 524 328 | 487 825 | 585 965 | -19 401 |
| Turnover growth rate (%) | 15,2 | 15,6 | 15,7 | -6,3 | 6,5 | 5 | 22,5 | 16,7 | - |
| Ebitda margin rate (%) | 1 | 4,9 | 9,2 | 5,3 | 1,6 | 2,9 | 12,6 | 3,2 | -1,2 |
| Operating margin rate (%) | 2,5 | 6,7 | 4,3 | 3,8 | 1,2 | 3,5 | 8,4 | 4,2 | -0,4 |
| Working Capital (turnover days) | 49,8 | 54,7 | 47,1 | 35,1 | 23,9 | 36,2 | 36,3 | 4,8 | -5 040,7 |
| Working Capital requirements (turnover days) | 25,6 | -3,5 | -14,3 | 33 | 26,9 | 17 | 53,2 | 7,4 | -5 039,1 |
| Net margin (%) | 1,8 | 5,4 | 1,5 | 2,2 | -1 | 2,6 | 2,6 | 3,8 | -0,1 |
| Added value / Turnover (%) | 24,8 | 26,2 | 30,9 | 32,4 | 22,3 | 32,7 | 35,5 | 30,4 | 37,5 |
| Wages and social charges (€) | 7 842 060 | 6 624 094 | 5 754 305 | 5 574 333 | 5 682 317 | 6 362 767 | 5 842 131 | 5 259 591 | 5 376 210 |
| Salaries / Turnover (%) | 25,6 | 24,9 | 25 | 28,1 | 26,8 | 32 | 30,8 | 34 | 40,5 |
Company Managers:
| Position | First Name | Last Name | Age | |
|---|---|---|---|---|
| Directeur général | Ariane | Ariche | 54 | |
| Directeur général | Francois | Da Silva | 49 |
Studies mentioning this company
The aesthetic medicine market - France
Other companies mentioned:
- Allergan plc
- Galderma
- Merz Pharmaceuticals
- La Roche-Posay
- Filorga Cosmétiques (Colgate Palmolive)
- Lierac (Laboratoire Native)
- Laboratoires Sebbin
- Arion
- Candela Medical
- Deleo
- Ipsen
- Clinique des Champs Elysées
- Lazeo
- Maison Lutetia
- Skincareagency
The aesthetic medicine market - United Kingdom
Other companies mentioned:
- Allergan plc
- Ipsen
- Merz Pharmaceuticals
- Cynosure
- Alma Lasers
The aesthetic medicine market - Italy
Other companies mentioned:
- Fidia Farmaceutici
- Decomedical
- ITS Group
- BTL
- EME Estetica
- Ipsen
- Merz Pharmaceuticals
- Allergan plc